Please login to the form below

Not currently logged in
Email:
Password:

EGFR inhibitor

This page shows the latest EGFR inhibitor news and features for those working in and with pharma, biotech and healthcare.

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

TAK-788 for non-small cell lung cancer:Phase 1/2 results with EGFR/HER2 inhibitor TAK-788 in non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations – ... a rare form of the disease resistant to current EGFR-targeting drugs – were

Latest news

  • AstraZeneca sells Losec rights as part of refocus strategy AstraZeneca sells Losec rights as part of refocus strategy

    AZ has being showing off its oncology power at ESMO, revealing positive date for its PARP inhibitor Lynparza (olaparib) in ovarian cancer and prostate cancer. ... The Merck &Co partnered drug has been driving sales for AZ, as well as its third generation

  • Tagrisso tops rival drugs on survival in first-line lung cancer Tagrisso tops rival drugs on survival in first-line lung cancer

    The improvement in OS came over other drugs in the EGFR inhibitor class, namely AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib), and according to AZ’s head of ... Now, the new data should help AZ continue to build momentum with Tagrisso

  • Hansoh Pharma shares head skyward after HKEX debut Hansoh Pharma shares head skyward after HKEX debut

    Six other new chemical entities are in the mid- to late-stage pipeline, including a third-generation EGFR inhibitor that could be a rival to AstraZeneca’s Tagrisso (osimertinib) in China ... and has been filed for EGFR-positive non-small cell lung

  • Oncology drives AstraZeneca, Genzyme boosts Sanofi Oncology drives AstraZeneca, Genzyme boosts Sanofi

    Third generation EGFR inhibitor Tagrisso is now the company’s top-selling drug, bringing in sales of $630m in the first quarter, almost double what the lung cancer drug made during ... Its Merck &Co-partnered PARP inhibitor Lynparza, which has

  • Chi-Med goes for third IPO in Hong Kong Chi-Med goes for third IPO in Hong Kong

    combination with the latter’s EGFR inhibitor Tagrisso (osimertinib) and PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in a series of proof-of-concept trials in solid tumours. ... Following after is surufatinib, an inhibitor of VEGF, FGFR and CSF-1R

More from news
Approximately 1 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    EGFR-TK) inhibitor, which has so far been approved in non-small cell lung cancer, albeit after a much-delayed, stop-start regulatory journey. ... If approved, the drug would complement AZ's other NSCLC drug, Iressa, which is approved in NSCLC patients

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma...
WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....

Infographics